Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivosidenib + oral azacitidine
- Development stage
- Unknown
- Lead developer
- Servier Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of ivosidenib, a small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), and Onureg (oral azacitidine), a hypomethylating agent. It is being investigated by the French Innovative Leukemia Organisation (FILO) as a maintenance treatment for patients aged 55 and older with IDH1-mutated acute myeloid leukemia (AML) who have achieved complete remission following intensive chemotherapy. Ivosidenib works by reducing levels of the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation, while oral azacitidine acts as a DNA methyltransferase inhibitor to induce DNA hypomethylation and restore normal gene expression. The combination aims to improve relapse-free survival in this high-risk patient population.
- Brand names
- Tibsovo
- Other names
- ivosidenib + Onuregivosidenib + CC-486
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on ivosidenib + oral azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivosidenib + oral azacitidine.